Cerus Co. (NASDAQ:CERS) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $6.50.

Several analysts recently weighed in on the company. BidaskClub upgraded Cerus from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th. Cantor Fitzgerald set a $5.00 price target on Cerus and gave the company a “buy” rating in a report on Monday, January 8th. Zacks Investment Research lowered Cerus from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. ValuEngine upgraded Cerus from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Finally, BTIG Research restated a “neutral” rating on shares of Cerus in a report on Friday, December 8th.

A number of hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its stake in Cerus by 5.6% in the second quarter. The Manufacturers Life Insurance Company now owns 87,994 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 4,688 shares during the period. Goldman Sachs Group Inc. increased its stake in Cerus by 8.0% in the second quarter. Goldman Sachs Group Inc. now owns 106,495 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 7,864 shares during the period. Voya Investment Management LLC increased its stake in Cerus by 22.0% in the second quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 10,570 shares during the period. UBS Asset Management Americas Inc. increased its stake in Cerus by 59.3% in the second quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 18,000 shares during the period. Finally, Senvest Management LLC increased its stake in Cerus by 0.7% in the third quarter. Senvest Management LLC now owns 2,960,398 shares of the biotechnology company’s stock worth $8,082,000 after purchasing an additional 20,000 shares during the period. Institutional investors and hedge funds own 55.72% of the company’s stock.

Shares of Cerus (NASDAQ CERS) opened at $4.11 on Friday. Cerus has a twelve month low of $1.93 and a twelve month high of $4.70. The firm has a market capitalization of $480.71, a price-to-earnings ratio of -6.97 and a beta of 1.93. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The company had revenue of $10.80 million for the quarter, compared to analyst estimates of $11.95 million. During the same quarter in the prior year, the firm posted ($0.14) EPS. Cerus’s quarterly revenue was up 5.9% compared to the same quarter last year. equities analysts forecast that Cerus will post -0.57 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/19/cerus-co-cers-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.